Freshpet
FRPT
$67.50
+2.09%
Freshpet, Inc. is a US-based manufacturer and marketer of premium refrigerated fresh pet food, sold primarily to dog owners through company-owned refrigerator units placed in grocery, mass, club, pet specialty, and natural retail channels, with all production occurring domestically and only marginal export sales to Canada, the UK, and Europe. The company is best characterized as a category creator and disruptor within the traditionally shelf-stable packaged pet food industry, using its proprietary in-store refrigeration footprint as both a physical moat and a merchandising differentiator against legacy kibble incumbents. The current investor narrative centers on Freshpet's transition from a capital-hungry growth story into a profitable, cash-generative franchise, evidenced by a swing to positive free cash flow and sharply improved operating margins in recent quarters. Debate among investors now hinges on whether the company can sustain double-digit revenue growth while holding its newly achieved margin structure, and whether the stock's recent recovery from its spring lows reflects durable earnings power or simply a relief rally following a volatile year.…
FRPT
Freshpet
$67.50
Investment Opinion: Should I buy FRPT Today?
Rating: Buy. The core thesis is that Freshpet has successfully transitioned from a cash-burning growth story to a profitable, cash-generative franchise, evidenced by a swing to positive free cash flow of $160.56 million TTM and an operating margin of 18.31% in Q4 2025, while the stock trades at a multi-year valuation low (PS of 2.70x vs. 27.42x at year-end 2024). The analyst consensus of 'buy' (mean 1.72) with an average target of $83.50 (22.6% upside) supports this view, and even the lowest target of $70.00 is above the current price, indicating a favorable risk/reward setup.
Supporting evidence: (1) Valuation: The PS ratio of 2.70x is near the bottom of its historical range, and the trailing PE of 21.38x is well below the 99.39x at Q4 2024, suggesting the stock is inexpensive relative to its own history. (2) Revenue growth: Q4 2025 revenue grew 8.57% year-over-year to $285.23 million, still solid though decelerating. (3) Profitability: Operating margin expanded to 18.31% in Q4 2025 from 7.38% in Q4 2024, and net income turned positive at $33.82 million. (4) Cash flow: TTM free cash flow of $160.56 million and a current ratio of 5.54 provide financial flexibility. (5) Analyst targets: The average target of $83.50 implies 22.6% upside, and the high target of $104.00 implies 53% upside. Without industry average data, we note that the EV/EBITDA of 18.64x is moderate for a branded consumer grower.
Risks and conditions: The biggest risks are (1) gross margin compression, which fell 570 basis points year-over-year to 36.75% in Q4 2025, and (2) revenue deceleration, with growth slowing to 8.57% and sequential declines. This Buy rating would upgrade to a Strong Buy if gross margins stabilize above 38% and revenue growth re-accelerates above 10%, or downgrade to Hold if gross margins fall below 35% or revenue growth drops below 5%. Valuation verdict: The stock appears undervalued relative to its own history (PS of 2.70x vs. 27.42x) and fairly valued relative to peers given its growth and margin profile, offering a favorable risk/reward for long-term investors.
Sign up to view all
FRPT 12-Month Price Forecast
The forward-looking view is bullish, driven by the company's successful transition to profitability and cash generation, which is not yet fully reflected in the valuation. The stock trades at a significant discount to its historical multiples, and the analyst community is overwhelmingly positive with a consensus 'buy' rating and targets uniformly above the current price. However, confidence is medium due to the recent gross margin compression and revenue deceleration, which could undermine the bull case if not reversed. We would upgrade to high confidence if gross margins stabilize above 38% and revenue growth re-accelerates above 10%, and downgrade to neutral if gross margins fall below 35% or revenue growth drops below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Freshpet's 12-month outlook, with a consensus price target around $83.19 and implied upside of +23.2% versus the current price.
Average Target
$83.19
0 analysts
Implied Upside
+23.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$67 - $104
Analyst target range
Coverage is robust, with 16 analysts and a consensus recommendation of "buy" (mean rating of 1.72 on a scale where 1 is a strong buy). The average target price of $83.50 implies roughly 22.6% upside from the current $68.10, and notably even the lowest target of $70.00 sits about 2.8% above the current price — meaning the entire published range is above the market, an unusually bullish configuration that suggests analysts view the recent pullback as an opportunity rather than a warning. Consensus estimates call for EPS of $3.07 (range $3.01 to $3.14) on revenue of approximately $1.67 billion, which implies a forward PE near 22x on consensus numbers — materially below the 34.70x forward multiple in the valuation data, a discrepancy that likely reflects differing earnings definitions and is worth reconciling before acting. The target range of $70.00 to $104.00 is wide, spanning roughly 49% from low to high, which signals meaningful disagreement about the company's trajectory. The $104.00 high target implies roughly 53% upside and would require multiple expansion alongside sustained margin recovery and accelerating growth — essentially a re-rating back toward the premium valuation the stock once commanded. The $70.00 low target prices in a scenario of margin compression or growth stalling near current levels, offering only modest upside. Institutional ratings show a constructive tilt: Oppenheimer upgraded to Outperform from Perform in March 2026 and Morgan Stanley moved to Overweight from Equal Weight in February 2026, while Deutsche Bank, JP Morgan, and TD Cowen remain neutral or hold-rated — a split that explains the wide target dispersion and suggests the bull case is gaining adherents but is not yet consensus.
Bulls vs Bears: FRPT Investment Factors
The bull case currently has stronger evidence, driven by the dramatic profitability inflection (18.31% operating margin in Q4 2025), positive free cash flow of $160.56 million TTM, and a valuation that has de-rated to multi-year lows (PS of 2.70x vs. 27.42x at year-end 2024). However, the bear case is not without merit: gross margin compression of 570 basis points and decelerating revenue growth to 8.57% raise questions about the durability of the margin structure. The single most important tension is whether Freshpet can sustain its newly achieved margin levels while re-accelerating revenue growth; if gross margins stabilize and revenue growth re-accelerates, the stock could re-rate toward the analyst high target of $104, but if margin pressure persists, the downside could be significant given the high beta and concentrated business model.
Bullish
- Profitability inflection is real: Q4 2025 operating margin reached 18.31%, a dramatic swing from Q1 2025's -4.37% and well above Q4 2024's 7.38%. Net income of $33.82 million in Q4 2025 versus a $12.70 million loss in Q1 2025 shows the margin structure has fundamentally improved.
- Free cash flow turned positive: TTM free cash flow is $160.56 million, with Q4 2025 alone generating $109.56 million. This marks a major inflection from negative FCF in 2024, removing the historical dependence on external financing and de-risking the equity story.
- Analyst targets uniformly above price: The average target of $83.50 implies 22.6% upside, and even the lowest target of $70.00 is 2.8% above the current $68.10. With 16 analysts and a consensus 'buy' rating (mean 1.72), the entire published range is above the market.
- Valuation de-rated to multi-year lows: The PS ratio has collapsed from 27.42x at year-end 2024 to 2.70x currently, and the trailing PE has fallen from 99.39x to 21.38x. This compression reflects both earnings improvement and a much lower price per dollar of sales, potentially signaling a value opportunity.
Bearish
- Gross margin compression is alarming: Gross margin fell from 42.48% in Q4 2024 to 36.75% in Q4 2025, a 570 basis point decline. This is the single most important metric to watch given the company's premium positioning and could signal input cost inflation or mix deterioration.
- Revenue growth decelerating: Q4 2025 revenue grew 8.57% year-over-year to $285.23 million, down from the low-to-mid teens historically. Sequential revenue was essentially flat to down, with Q4 down 1.3% from Q3's $288.85 million, raising demand concerns.
- Forward PE inversion signals earnings decline: The forward PE of 34.70x is 62% higher than the trailing PE of 21.38x, implying the market expects earnings to fall from the tax-inflated trailing base. The Q3 2025 net income of $101.66 million was inflated by a $77.96 million deferred tax benefit.
- High volatility and drawdown risk: Beta of 1.778 means the stock is 78% more volatile than the market, and the maximum drawdown of -44.57% over the past year demonstrates significant downside risk. Position sizing should be materially smaller than a market-beta equivalent.
FRPT Technical Analysis
Freshpet is in a recovery uptrend that has repaired much of the damage from a severe mid-year drawdown. The stock is up 32.03% over the trailing year and 13.22% year-to-date, and at $68.10 it sits roughly 54.7% of the way through its 52-week range of $46.45 to $86.00 — meaning it has reclaimed the middle of the band but remains well below its highs, a positioning that reflects recovering momentum rather than overextension. The 44.57% maximum drawdown underscores how violent the prior decline was, and the current price represents a roughly 46.6% advance off the 52-week low, confirming that buyers have stepped in decisively. Short-term momentum is clearly positive and accelerating: the stock is up 6.79% over the past month and 19.62% over three months, with the 1-month gain outpacing the S&P 500's 1.15% by a relative strength spread of 5.64 points and the 3-month relative strength reaching 17.11 points. This contrasts with a 6-month change of -2.01% and a 6-month relative strength of -10.38, revealing a V-shaped pattern in which a spring collapse was followed by a powerful summer rally and a September pullback that has since been reversed. The most recent session added 2.93% on volume of roughly 1.03 million shares, suggesting institutional participation in the move rather than thin drift. Key resistance sits at the $86.00 52-week high, roughly 26.3% above the current price; a breakout there would signal a full trend reset and likely invite momentum buyers. Support is anchored at the $46.45 52-week low, about 31.8% below current levels, with intermediate support in the $57-$60 zone where the September consolidation occurred. With a beta of 1.778, Freshpet is roughly 78% more volatile than the market, meaning position sizing should be materially smaller than a market-beta equivalent and stop-loss discipline is essential given the stock's demonstrated capacity for 40%+ drawdowns.
Beta
1.78
1.78x market volatility
Max Drawdown
-44.6%
Largest decline past year
52-Week Range
$46-$86
Price range past year
Annual Return
+33.4%
Cumulative gain past year
| Period | FRPT Return | S&P 500 |
|---|---|---|
| 1m | +17.3% | -0.9% |
| 3m | +13.4% | +1.2% |
| 6m | +3.6% | +4.9% |
| 1y | +33.4% | +11.2% |
| ytd | +12.2% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
FRPT Fundamental Analysis
Freshpet's revenue trajectory remains solidly growth-oriented but is decelerating from its historical pace. The most recent quarter (Q4 2025) delivered revenue of $285.23 million, up 8.57% year-over-year versus $262.71 million in Q4 2024, while the prior three quarters came in at $288.85 million (Q3 2025), $264.69 million (Q2 2025), and $263.25 million (Q1 2025) — a sequential pattern that is essentially flat to modestly down, indicating that top-line growth is now in the high-single-digit range rather than the low-to-mid teens the company once posted. The Q3 2025 print of $288.85 million was actually the highest of the trailing four quarters, so the Q4 sequential dip of about 1.3% warrants monitoring for demand softness or seasonal/channel timing effects. With a single reportable segment and dog food representing well north of 90% of sales, there is no diversification buffer — the investment case is a concentrated bet on continued household penetration of fresh pet food in the US. Profitability has inflected meaningfully and is the core of the bull case. Q4 2025 net income was $33.82 million on a 36.75% gross margin and 18.31% operating margin, a dramatic improvement from Q1 2025's net loss of $12.70 million and negative 4.37% operating margin, and well ahead of Q4 2024's $18.12 million profit at a 7.38% operating margin. The Q3 2025 net income of $101.66 million was inflated by a $77.96 million deferred tax benefit (effective tax rate of -328.9%), so the underlying operating profit of $25.74 million at an 8.91% margin is the cleaner read — still a sharp sequential step-up from Q2's $17.80 million. Gross margin has compressed from 42.48% in Q4 2024 to 36.75% in Q4 2025, a roughly 570 basis point decline that likely reflects input cost inflation, mix, or plant ramp costs, and this is the single most important metric to watch given the company's premium positioning. Balance sheet health is a clear strength: the current ratio stands at 5.54, debt-to-equity is a modest 0.46, and cash at the end of Q4 2025 was $277.98 million against quarterly operating cash flow of $55.11 million and capital expenditure of $54.46 million. Free cash flow turned decisively positive at $109.56 million in Q4 2025 and $160.56 million on a trailing-twelve-month basis, a major inflection from the negative FCF prints of 2024, with ROE at 11.51% and ROA at 3.49%. The company is now self-funding its growth, which removes the historical dependence on external financing and materially de-risks the equity story.
Quarterly Revenue
$285229000.0B
2025-12
Revenue YoY Growth
+8.6%
YoY Comparison
Gross Margin
36.8%
Latest Quarter
Free Cash Flow
$160561000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is FRPT Overvalued?
Because Freshpet is profitable on a trailing basis (EPS of $0.047 and net income of $33.82 million in the latest quarter), the PE ratio is the appropriate primary metric, though the trailing figure must be treated with caution given the tax-benefit distortion in Q3 2025. The trailing PE of 21.38x compares with a forward PE of 34.70x — an unusual inversion in which the forward multiple is 62% higher than the trailing multiple, implying the market expects earnings to decline from a tax-inflated trailing base rather than grow. On the cleaner forward basis, the 34.70x multiple is the more economically meaningful number, and it sits alongside a PS ratio of 2.70x, EV/Sales of 2.82x, EV/EBITDA of 18.64x, and a PEG of just 0.11 — the latter suggesting that on expected growth-adjusted terms the stock screens as inexpensive, though the PEG is likely distorted by the depressed trailing earnings base. Peer comparison is constrained by the absence of a supplied industry-average multiple set, but contextually Freshpet's 2.70x PS and 18.64x EV/EBITDA are moderate for a branded consumer staples grower with high-single-digit revenue growth, and its 38.58% gross margin and 8.62% operating margin are below the profitability profile of large-cap packaged food peers, arguing that a premium multiple is not obviously warranted. The stock's own historical band tells a striking story of de-rating: the PS ratio has collapsed from 27.42x at year-end 2024 and 26.19x in Q3 2024 to 10.42x at Q4 2025 and just 2.70x currently, while the PE ratio has fallen from 99.39x at Q4 2024 to 21.38x today. This compression reflects both genuine earnings improvement and a substantial contraction in what investors are willing to pay per dollar of sales — the stock is now near the bottom of its multi-year valuation band, which could signal either a value opportunity if margins hold, or lingering skepticism about the durability of the profit inflection.
PE
21.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~139x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin sustainability and revenue concentration. Gross margin has compressed from 42.48% in Q4 2024 to 36.75% in Q4 2025, a 570 basis point decline that, if continued, would severely pressure profitability given the company's premium positioning. Revenue growth has decelerated to 8.57% year-over-year in Q4 2025, and the sequential decline of 1.3% from Q3 raises concerns about demand softness. With dog food representing over 90% of sales, there is no diversification buffer, and the company's single-segment structure means any weakness in the fresh pet food category directly hits the top line. Additionally, the Q3 2025 net income was inflated by a $77.96 million deferred tax benefit, so the underlying operating profit of $25.74 million (8.91% margin) is a cleaner but less impressive read. The forward PE of 34.70x is 62% higher than the trailing PE of 21.38x, implying the market expects earnings to decline from the tax-inflated base, which adds valuation risk if earnings disappoint.
Market and competitive risks are amplified by the stock's high beta of 1.778, meaning it is 78% more volatile than the market and vulnerable to sharp selloffs during risk-off periods. The stock has already experienced a maximum drawdown of -44.57% over the past year, and its 6-month change of -2.01% (with relative strength of -10.38 versus the S&P 500) shows it can lag significantly during certain periods. Competitive disruption from legacy kibble incumbents or new entrants in the fresh pet food space could pressure pricing and market share, especially as the company faces input cost inflation. Regulatory headwinds, such as changes in pet food labeling or ingredient standards, could also impact operations. The recent news flow is empty, but the analyst split (Oppenheimer and Morgan Stanley upgraded, while Deutsche Bank, JP Morgan, and TD Cowen remain neutral) suggests the bull case is gaining adherents but is not yet consensus, leaving room for sentiment swings.
Worst-case scenario: A combination of continued gross margin compression (e.g., falling below 35%), revenue growth stalling below 5%, and a market rotation away from high-beta consumer names could trigger a sharp decline. The 52-week low of $46.45 represents a 31.8% downside from the current price of $68.10, and the analyst low target of $70.00 is actually above the current price, so the bear case is not fully priced in by analysts. However, if margin pressure intensifies and growth decelerates, the stock could retest the 52-week low, implying a loss of approximately 32%. Given the beta of 1.778, a market correction of 10% could translate to a 17.8% decline in FRPT, exacerbating the downside. Investors should be prepared for volatility and consider position sizing accordingly.
FAQ
The key risks are ranked by severity: (1) Gross margin compression—gross margin fell 570 basis points year-over-year to 36.75% in Q4 2025, and further decline could severely impact profitability. (2) Revenue deceleration—growth slowed to 8.57% in Q4 2025, and sequential revenue declined 1.3% from Q3, raising demand concerns. (3) High volatility—beta of 1.778 and a maximum drawdown of -44.57% mean the stock can experience sharp declines during market stress. (4) Concentration risk—over 90% of sales come from dog food, leaving little diversification. Additionally, the forward PE inversion (34.70x vs. trailing 21.38x) suggests the market expects earnings to decline, which could pressure the stock if earnings disappoint.
The 12-month forecast has three scenarios: Bull case (30% probability) targets $83.50-$104.00, assuming gross margin recovery and revenue re-acceleration; Base case (50% probability) targets $70.00-$83.50, assuming stable margins and high-single-digit growth; Bear case (20% probability) targets $46.45-$70.00, assuming continued margin compression and growth deceleration. The most likely scenario is the base case, with a target around the analyst average of $83.50, driven by the company's profitability inflection and positive free cash flow. The key assumption is that gross margins stabilize around 37-38% and revenue growth remains in the 8-10% range.
FRPT appears undervalued relative to its own history. The PS ratio of 2.70x is a fraction of the 27.42x at year-end 2024 and 10.42x at Q4 2025, and the trailing PE of 21.38x is well below the 99.39x at Q4 2024. The forward PE of 34.70x is higher than trailing due to the tax-inflated Q3 2025 earnings, but on a clean operating basis, the stock trades at a reasonable multiple for a company with high-single-digit revenue growth and improving margins. Compared to peers, without industry average data, the EV/EBITDA of 18.64x is moderate for a branded consumer grower. The market appears to be pricing in skepticism about the durability of the margin inflection, offering potential upside if margins hold.
From a risk/reward perspective, FRPT appears to be a good buy for investors with a medium-to-long-term horizon and tolerance for volatility. The stock trades at $68.10, with an average analyst target of $83.50 implying 22.6% upside, and even the lowest target of $70.00 is above the current price. The valuation has de-rated to multi-year lows (PS of 2.70x vs. 27.42x at year-end 2024), while profitability has inflected positively (18.31% operating margin in Q4 2025). However, the biggest downside risk is a retest of the 52-week low of $46.45, representing a 31.8% decline, driven by gross margin compression and revenue deceleration. Therefore, it is a good buy for growth-oriented investors who can withstand a potential 30% drawdown and believe in the long-term fresh pet food trend, but position sizing should be moderated given the beta of 1.778.
FRPT is more suitable for long-term investment (minimum 2-3 years) given its growth stage, high volatility (beta of 1.778), and the ongoing transition to sustained profitability. The company does not pay a dividend (payout ratio 0%), so returns depend entirely on capital appreciation. Earnings visibility is improving but still uncertain, as evidenced by the wide analyst target range ($70-$104) and the recent margin volatility. Short-term trading could be risky due to the stock's history of sharp drawdowns (-44.57% max) and sensitivity to quarterly earnings. A suggested minimum holding period of 2-3 years allows time for the margin story to play out and for the company to demonstrate consistent free cash flow generation.